Skip to content

Study · Not a test of the peptide alone · 2008

8 results

Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria.

Zhang Y, Chen H, Li YM, Zheng SS, Chen YG, Li LJ, Zhou L, Xie HY, Praseedom RK

The Journal of infectious diseases1 Sept 2008Cited by 40 (Europe PMC)

PMID18613793 (opens in a new tab)DOI10.1086/590500 (opens in a new tab)PepBankPUB-18613793
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with sepsis from carbapenem-resistant bacteria, thymosin alpha‑1 plus ulinastatin with carbapenems gave a better APACHE II score than carbapenems with placebo.

    In plain wordsIn adults with sepsis from resistant bacteria, thymosin alpha‑1 with ulinastatin and antibiotics gave a better illness-severity score than antibiotics with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedAPACHE II score
    Study

    n = 120

    Comparator
    Carbapenems plus placebo
    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    When the 2 groups were compared, the CTU group exhibited a better performance with respect to organ failure scores such as the Acute Physiology and Chronic Health Evaluation II score, the Multiple Organ Failure Score, and the Glasgow Coma Scale.
    1 context sentence
    Summary · context
    A total of 120 patients received a diagnosis of sepsis caused by infection with carbapenem-resistant bacteria and satisfied the study enrollment criteria. Sixty patients received carbapenems combined with thymosin alpha(1) and ulinastatin (the CTU group), and the other 60 patients were treated with…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with sepsis from carbapenem-resistant bacteria, thymosin alpha‑1 plus ulinastatin with carbapenems gave a better Multiple Organ Failure Score than carbapenems with placebo.

    In plain wordsIn adults with sepsis from resistant bacteria, thymosin alpha‑1 with ulinastatin and antibiotics gave a better organ-failure score than antibiotics with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedMultiple Organ Failure Score
    Study

    n = 120

    Comparator
    Carbapenems plus placebo
    Outcome group
    Intensive care and hospital outcomes · Whole body

    Source sentences

    Summary
    When the 2 groups were compared, the CTU group exhibited a better performance with respect to organ failure scores such as the Acute Physiology and Chronic Health Evaluation II score, the Multiple Organ Failure Score, and the Glasgow Coma Scale.
    1 context sentence
    Summary · context
    A total of 120 patients received a diagnosis of sepsis caused by infection with carbapenem-resistant bacteria and satisfied the study enrollment criteria. Sixty patients received carbapenems combined with thymosin alpha(1) and ulinastatin (the CTU group), and the other 60 patients were treated with…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with sepsis from carbapenem-resistant bacteria, thymosin alpha‑1 plus ulinastatin with carbapenems gave a better Glasgow Coma Scale result than carbapenems with placebo.

    In plain wordsIn adults with sepsis from resistant bacteria, thymosin alpha‑1 with ulinastatin and antibiotics gave a better consciousness score than antibiotics with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedGlasgow Coma Scale
    Study

    n = 120

    Comparator
    Carbapenems plus placebo
    Outcome group
    Intensive care and hospital outcomes · Nervous system and cognition

    Source sentences

    Summary
    When the 2 groups were compared, the CTU group exhibited a better performance with respect to organ failure scores such as the Acute Physiology and Chronic Health Evaluation II score, the Multiple Organ Failure Score, and the Glasgow Coma Scale.
    1 context sentence
    Summary · context
    A total of 120 patients received a diagnosis of sepsis caused by infection with carbapenem-resistant bacteria and satisfied the study enrollment criteria. Sixty patients received carbapenems combined with thymosin alpha(1) and ulinastatin (the CTU group), and the other 60 patients were treated with…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with sepsis from carbapenem-resistant bacteria, CD4(+)CD8(+) count improved significantly after treatment with thymosin alpha‑1 plus ulinastatin and carbapenems.

    In plain wordsIn adults with sepsis from resistant bacteria, a type of immune cell count improved after thymosin alpha‑1 with ulinastatin and antibiotics.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+CD8+ count
    Study

    n = 120

    Comparator
    Carbapenems plus placebo
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The CTU group also showed significant improvements in CD4(+)CD8(+) count after initiation of treatment.
    1 context sentence
    Summary · context
    A total of 120 patients received a diagnosis of sepsis caused by infection with carbapenem-resistant bacteria and satisfied the study enrollment criteria. Sixty patients received carbapenems combined with thymosin alpha(1) and ulinastatin (the CTU group), and the other 60 patients were treated with…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with sepsis from carbapenem-resistant bacteria, thymosin alpha‑1 plus ulinastatin with carbapenems modulated the balance of proinflammatory mediators and anti-inflammatory cytokines better than carbapenems with placebo.

    In plain wordsIn adults with sepsis from resistant bacteria, thymosin alpha‑1 with ulinastatin and antibiotics balanced immune signals better than antibiotics with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedBalance of proinflammatory and anti-inflammatory cytokines
    Study

    n = 120

    Comparator
    Carbapenems plus placebo
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    compared with the CP group, in the CTU group the balance between proinflammatory mediators (such as tumor necrosis factor-alpha, interleukin [IL]-1beta, IL-6, and IL-8) and anti-inflammatory cytokines (including IL-4 and IL-10) was better modulated
    1 context sentence
    Summary · context
    A total of 120 patients received a diagnosis of sepsis caused by infection with carbapenem-resistant bacteria and satisfied the study enrollment criteria. Sixty patients received carbapenems combined with thymosin alpha(1) and ulinastatin (the CTU group), and the other 60 patients were treated with…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with sepsis from carbapenem-resistant bacteria, cumulative survival with thymosin alpha‑1 plus ulinastatin and carbapenems exceeded that with carbapenems and placebo by 17.8% at day 28.

    In plain wordsIn adults with sepsis from resistant bacteria, more people survived to day 28 with thymosin alpha‑1, ulinastatin and antibiotics than with antibiotics and placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCumulative survival difference at day 28
    Study

    n = 120

    Comparator
    Carbapenems plus placebo
    Outcome group
    Mortality · Whole body

    Measurements

    Cumulative survival difference
    17.8%
    day 28

    Source sentences

    Summary
    the cumulative survival rate of the CTU group exceeded that of the CP group by 17.8% at day 28
    1 context sentence
    Summary · context
    A total of 120 patients received a diagnosis of sepsis caused by infection with carbapenem-resistant bacteria and satisfied the study enrollment criteria. Sixty patients received carbapenems combined with thymosin alpha(1) and ulinastatin (the CTU group), and the other 60 patients were treated with…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with sepsis from carbapenem-resistant bacteria, cumulative survival with thymosin alpha‑1 plus ulinastatin and carbapenems exceeded that with carbapenems and placebo by 25.9% at day 60.

    In plain wordsIn adults with sepsis from resistant bacteria, more people survived to day 60 with thymosin alpha‑1, ulinastatin and antibiotics than with antibiotics and placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCumulative survival difference at day 60
    Study

    n = 120

    Comparator
    Carbapenems plus placebo
    Outcome group
    Mortality · Whole body

    Measurements

    Cumulative survival difference
    25.9%
    day 60

    Source sentences

    Summary
    the cumulative survival rate of the CTU group exceeded that of the CP group by 17.8% at day 28, 25.9% at day 60
    1 context sentence
    Summary · context
    A total of 120 patients received a diagnosis of sepsis caused by infection with carbapenem-resistant bacteria and satisfied the study enrollment criteria. Sixty patients received carbapenems combined with thymosin alpha(1) and ulinastatin (the CTU group), and the other 60 patients were treated with…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  8. 08HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In adults with sepsis from carbapenem-resistant bacteria, cumulative survival with thymosin alpha‑1 plus ulinastatin and carbapenems exceeded that with carbapenems and placebo by 27.4% at day 90.

    In plain wordsIn adults with sepsis from resistant bacteria, more people survived to day 90 with thymosin alpha‑1, ulinastatin and antibiotics than with antibiotics and placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCumulative survival difference at day 90
    Study

    n = 120

    Comparator
    Carbapenems plus placebo
    Outcome group
    Mortality · Whole body

    Measurements

    Cumulative survival difference
    27.4%
    day 90

    Source sentences

    Summary
    the cumulative survival rate of the CTU group exceeded that of the CP group by 17.8% at day 28, 25.9% at day 60, and 27.4% at day 90
    1 context sentence
    Summary · context
    A total of 120 patients received a diagnosis of sepsis caused by infection with carbapenem-resistant bacteria and satisfied the study enrollment criteria. Sixty patients received carbapenems combined with thymosin alpha(1) and ulinastatin (the CTU group), and the other 60 patients were treated with…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.